Marlies Sproll - MorphoSys Executive
Executive
Dr. Marlies Sproll was Chief Scientific Officer, Member of the Management Board of MorphoSys AG since November 1, 2005. She is responsible for antibody discovery and predevelopment, technology development, protein sciences, alliance management and intellectual property. In 2000 she joined MorphoSys AG as Head of Research and Development Department. Before joining the Company, Dr. Sproll worked for seven years at the Vienna research facility of Boehringer Ingelheim. After initially being employed as laboratory head, she later took over international project management for several development projects of therapeutic antibodies as well as antibody conjugates and vaccines in the field of oncology. From 1988 to 1993, Dr. Sproll was laboratory leader at Merck KGaA in Darmstadt, Germany, where she was involved in the preclinical development of therapeutic antibodies since 2005.
| Age | 66 |
| Tenure | 19 years |
| Professional Marks | Ph.D |
| Phone | 49 89 899 27 0 |
| Web | https://www.morphosys.com |
MorphoSys Management Efficiency
The company has Return on Asset of (0.1384) % which means that on every $100 spent on assets, it lost $0.1384. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.838) %, meaning that it generated no profit with money invested by stockholders. MorphoSys' management efficiency ratios could be used to measure how well MorphoSys manages its routine affairs as well as how well it operates its assets and liabilities.MorphoSys AG ADR has 635.93 M in debt with debt to equity (D/E) ratio of 2.32, meaning that the company heavily relies on borrowing funds for operations. MorphoSys AG ADR has a current ratio of 2.92, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for MorphoSys to invest in growth at high rates of return.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jason Fredette | Mersana Therapeutics | N/A | |
| David MD | Mineralys Therapeutics, Common | 69 | |
| Vineeta Belanger | Lyra Therapeutics | N/A | |
| Robert MD | Lyra Therapeutics | N/A | |
| Philip JD | Monte Rosa Therapeutics | 45 | |
| Chad Cowan | Century Therapeutics | N/A | |
| Christian JD | Gossamer Bio | 57 | |
| Elvia Cowan | Vaxcyte | 51 | |
| Matthew Moore | Ventyx Biosciences | 51 | |
| Heba Nowyhed | Arcellx | N/A | |
| Mary CPA | Cullinan Oncology LLC | 60 | |
| Nick MD | Century Therapeutics | N/A | |
| Timothy Lowinger | Mersana Therapeutics | 60 | |
| MPH DO | Kronos Bio | 59 | |
| Michael MD | Century Therapeutics | 53 | |
| MBA MD | Replimune Group | 58 | |
| Isabel Chiu | C4 Therapeutics | N/A | |
| Caryn Peterson | Gossamer Bio | 65 | |
| Jolie JD | C4 Therapeutics | 47 | |
| Sandra Gardiner | Kronos Bio | 58 | |
| JoAnn Suzich | Immunocore Holdings | N/A | |
Management Performance
| Return On Equity | -1.84 | |||
| Return On Asset | -0.14 |
MorphoSys AG ADR Leadership Team
Elected by the shareholders, the MorphoSys' board of directors comprises two types of representatives: MorphoSys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MorphoSys. The board's role is to monitor MorphoSys' management team and ensure that shareholders' interests are well served. MorphoSys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MorphoSys' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gnter Wellnhofer, Head Operations | ||
| Maria Castresana, VP HR | ||
| Anja Pomrehn, VP Relations | ||
| Lukas Gilgen, Chief Officer | ||
| Lucinda Crabtree, CFO Board | ||
| Charlotte Lohmann, Compliance Legal | ||
| Sung Lee, CFO Board | ||
| Tim MD, Chief Officer | ||
| Marlies Sproll, Chief Scientific Officer, Member of the Management Board | ||
| Julia Neugebauer, Head Relations | ||
| Barbara KrebsPohl, Chief Officer | ||
| Arkadius MBA, Chief Officer | ||
| Ralf Ostendorp, Head CMC | ||
| Harald Watzka, Head Management | ||
| Lara Weber, Corp Controlling | ||
| JeanPaul MD, MD Board | ||
| Margit Urban, Head Technologies | ||
| Yen Chua, Head Operations | ||
| Klaus Wall, Head Tax | ||
| Thomas Biegi, VP Communications |
MorphoSys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MorphoSys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.84 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (1.91) % | |||
| Operating Margin | (9.60) % | |||
| Current Valuation | 2.68 B | |||
| Shares Outstanding | 150.65 M | |||
| Shares Owned By Institutions | 7.44 % | |||
| Number Of Shares Shorted | 135.04 K | |||
| Price To Earning | 4.52 X | |||
| Price To Book | 53.81 X |
Pair Trading with MorphoSys
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MorphoSys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MorphoSys will appreciate offsetting losses from the drop in the long position's value.Moving against MorphoSys Stock
| 0.65 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
| 0.56 | MSFT | Microsoft Aggressive Push | PairCorr |
| 0.34 | T | ATT Inc Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.34 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
The ability to find closely correlated positions to MorphoSys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MorphoSys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MorphoSys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MorphoSys AG ADR to buy it.
The correlation of MorphoSys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MorphoSys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MorphoSys AG ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MorphoSys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in MorphoSys Stock
If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |